ARHGEF7

Across TCGA pan-cancer cohorts, ARHGEF7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGEF7 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ARHGEF7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and READ are the cancer types where ARHGEF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.953	0.823	.006	32	view →
READ	DFS	Median	IV	0.255	0.628	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGEF7–THYM (OS)

Open the THYM breakdown →